MEDICLIN AG (MED.DE) Stock Fundamental Analysis
FRA:MED - Deutsche Boerse Ag - DE0006595101 - Common Stock - Currency: EUR
Overall MED gets a fundamental rating of 5 out of 10. We evaluated MED against 24 industry peers in the Health Care Providers & Services industry. While MED is still in line with the averages on profitability rating, there are concerns on its financial health. A decent growth rate in combination with a cheap valuation! Better keep an eye on MED.
1. Profitability
1.1 Basic Checks
In the past year MED was profitable.
MED had a positive operating cash flow in the past year.
In multiple years MED reported negative net income over the last 5 years.
In the past 5 years MED always reported a positive cash flow from operatings.
1.2 Ratios
Looking at the Return On Assets, with a value of 2.91%, MED is in line with its industry, outperforming 58.33% of the companies in the same industry.
Looking at the Return On Equity, with a value of 11.67%, MED is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
MED has a better Return On Invested Capital (5.78%) than 62.50% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for MED is below the industry average of 6.16%.
The 3 year average ROIC (3.46%) for MED is below the current ROIC(5.78%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.91% | ||
| ROE | 11.67% | ||
| ROIC | 5.78% |
ROA(3y)0.85%
ROA(5y)0.34%
ROE(3y)3.39%
ROE(5y)1.18%
ROIC(3y)3.46%
ROIC(5y)2.35%
1.3 Margins
Looking at the Profit Margin, with a value of 3.41%, MED is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
MED's Profit Margin has improved in the last couple of years.
MED has a Operating Margin of 7.13%. This is comparable to the rest of the industry: MED outperforms 50.00% of its industry peers.
MED's Operating Margin has improved in the last couple of years.
With an excellent Gross Margin value of 83.54%, MED belongs to the best of the industry, outperforming 83.33% of the companies in the same industry.
MED's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.13% | ||
| PM (TTM) | 3.41% | ||
| GM | 83.54% |
OM growth 3Y67.11%
OM growth 5Y19.19%
PM growth 3Y148.06%
PM growth 5Y18.19%
GM growth 3Y0.37%
GM growth 5Y0.18%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), MED is creating some value.
MED has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, MED has about the same amount of shares outstanding.
Compared to 1 year ago, MED has an improved debt to assets ratio.
2.2 Solvency
MED has an Altman-Z score of 1.63. This is a bad value and indicates that MED is not financially healthy and even has some risk of bankruptcy.
MED has a Altman-Z score (1.63) which is comparable to the rest of the industry.
The Debt to FCF ratio of MED is 13.36, which is on the high side as it means it would take MED, 13.36 years of fcf income to pay off all of its debts.
With a Debt to FCF ratio value of 13.36, MED is not doing good in the industry: 70.83% of the companies in the same industry are doing better.
MED has a Debt/Equity ratio of 1.92. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of MED (1.92) is worse than 70.83% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.92 | ||
| Debt/FCF | 13.36 | ||
| Altman-Z | 1.63 |
ROIC/WACC1.2
WACC4.8%
2.3 Liquidity
MED has a Current Ratio of 1.81. This is a normal value and indicates that MED is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.81, MED is in the better half of the industry, outperforming 79.17% of the companies in the same industry.
MED has a Quick Ratio of 1.76. This is a normal value and indicates that MED is financially healthy and should not expect problems in meeting its short term obligations.
MED has a better Quick ratio (1.76) than 91.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.81 | ||
| Quick Ratio | 1.76 |
3. Growth
3.1 Past
MED shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 541.24%, which is quite impressive.
MED shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 20.79% yearly.
MED shows a decrease in Revenue. In the last year, the revenue decreased by -1.47%.
MED shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.19% yearly.
EPS 1Y (TTM)541.24%
EPS 3Y157.01%
EPS 5Y20.79%
EPS Q2Q%88.47%
Revenue 1Y (TTM)-1.47%
Revenue growth 3Y3.65%
Revenue growth 5Y2.19%
Sales Q2Q%0.33%
3.2 Future
Based on estimates for the next years, MED will show a small growth in Earnings Per Share. The EPS will grow by 6.48% on average per year.
Based on estimates for the next years, MED will show a small growth in Revenue. The Revenue will grow by 2.80% on average per year.
EPS Next Y20.73%
EPS Next 2Y12.62%
EPS Next 3Y6.48%
EPS Next 5YN/A
Revenue Next Year4.55%
Revenue Next 2Y2.95%
Revenue Next 3Y2.8%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
MED is valuated cheaply with a Price/Earnings ratio of 5.35.
Based on the Price/Earnings ratio, MED is valued cheaper than 95.83% of the companies in the same industry.
MED's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.30.
The Price/Forward Earnings ratio is 5.60, which indicates a rather cheap valuation of MED.
Based on the Price/Forward Earnings ratio, MED is valued cheaply inside the industry as 95.83% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.76, MED is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.35 | ||
| Fwd PE | 5.6 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, MED is valued cheaper than 91.67% of the companies in the same industry.
83.33% of the companies in the same industry are more expensive than MED, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4.08 | ||
| EV/EBITDA | 3.32 |
4.3 Compensation for Growth
MED's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of MED may justify a higher PE ratio.
PEG (NY)0.26
PEG (5Y)0.26
EPS Next 2Y12.62%
EPS Next 3Y6.48%
5. Dividend
5.1 Amount
MED has a Yearly Dividend Yield of 1.36%.
MED's Dividend Yield is comparable with the industry average which is at 2.80.
Compared to an average S&P500 Dividend Yield of 2.35, MED's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.36% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DP0%
EPS Next 2Y12.62%
EPS Next 3Y6.48%
FRA:MED (7/10/2025, 7:00:00 PM)
2.94
-0.06 (-2%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners1.7%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap139.65M
Analysts83.33
Price Target4.79 (62.93%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.36% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)4.44%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)1.02%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.81%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.35 | ||
| Fwd PE | 5.6 | ||
| P/S | 0.18 | ||
| P/FCF | 4.08 | ||
| P/OCF | 1.73 | ||
| P/B | 0.62 | ||
| P/tB | 0.7 | ||
| EV/EBITDA | 3.32 |
EPS(TTM)0.55
EY18.71%
EPS(NY)0.53
Fwd EY17.86%
FCF(TTM)0.72
FCFY24.49%
OCF(TTM)1.69
OCFY57.65%
SpS16.12
BVpS4.71
TBVpS4.19
PEG (NY)0.26
PEG (5Y)0.26
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.91% | ||
| ROE | 11.67% | ||
| ROCE | 7.45% | ||
| ROIC | 5.78% | ||
| ROICexc | 7.6% | ||
| ROICexgc | 7.95% | ||
| OM | 7.13% | ||
| PM (TTM) | 3.41% | ||
| GM | 83.54% | ||
| FCFM | 4.47% |
ROA(3y)0.85%
ROA(5y)0.34%
ROE(3y)3.39%
ROE(5y)1.18%
ROIC(3y)3.46%
ROIC(5y)2.35%
ROICexc(3y)4.47%
ROICexc(5y)3.03%
ROICexgc(3y)4.72%
ROICexgc(5y)3.22%
ROCE(3y)4.46%
ROCE(5y)3.03%
ROICexcg growth 3Y64.29%
ROICexcg growth 5Y26.18%
ROICexc growth 3Y68.25%
ROICexc growth 5Y27.23%
OM growth 3Y67.11%
OM growth 5Y19.19%
PM growth 3Y148.06%
PM growth 5Y18.19%
GM growth 3Y0.37%
GM growth 5Y0.18%
F-Score6
Asset Turnover0.85
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.92 | ||
| Debt/FCF | 13.36 | ||
| Debt/EBITDA | 4.06 | ||
| Cap/Depr | 90.73% | ||
| Cap/Sales | 6.05% | ||
| Interest Coverage | 2.42 | ||
| Cash Conversion | 76.2% | ||
| Profit Quality | 131.16% | ||
| Current Ratio | 1.81 | ||
| Quick Ratio | 1.76 | ||
| Altman-Z | 1.63 |
F-Score6
WACC4.8%
ROIC/WACC1.2
Cap/Depr(3y)56.34%
Cap/Depr(5y)45.08%
Cap/Sales(3y)4.78%
Cap/Sales(5y)4.13%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)541.24%
EPS 3Y157.01%
EPS 5Y20.79%
EPS Q2Q%88.47%
EPS Next Y20.73%
EPS Next 2Y12.62%
EPS Next 3Y6.48%
EPS Next 5YN/A
Revenue 1Y (TTM)-1.47%
Revenue growth 3Y3.65%
Revenue growth 5Y2.19%
Sales Q2Q%0.33%
Revenue Next Year4.55%
Revenue Next 2Y2.95%
Revenue Next 3Y2.8%
Revenue Next 5YN/A
EBIT growth 1Y195.75%
EBIT growth 3Y73.21%
EBIT growth 5Y21.8%
EBIT Next Year131.21%
EBIT Next 3Y31.07%
EBIT Next 5YN/A
FCF growth 1Y276.49%
FCF growth 3Y-17.96%
FCF growth 5Y7.78%
OCF growth 1Y107.99%
OCF growth 3Y-0.57%
OCF growth 5Y2.97%